Clinical characteristics of Upper Gastrointestinal Tract Bleeding and Outcomes in COVID-19 patients- A single centre retrospective descriptive study

Autor: TAN Yee Wen, Ko-Ping, TIANG, MOHD Muzakkir Bin Ibrahim, THARANITHARAN R Rajasingam, QUEK Yeow Ling
Jazyk: angličtina
Rok vydání: 2021
Předmět:
DOI: 10.5281/zenodo.5457585
Popis: Introduction: Anticoagulants and corticosteroids are the main treatment for COVID-19, therefore increases the incidence of Upper Gastrointestinal tract Bleeding (UGIB) in these patients. The aim of this study is to investigate the incidence and characteristics of UGIB among COVID -19 patients in our centre to determine the best management approach. Methodology: Demographics, endoscopic findings, intervention and outcomes of UGIB among COVID-19 patients has been retrospectively evaluated for patient admitted to Sungai Buloh Hospital from March 2020 to March 2021. Results: The incidence of UGIB among COVID-19 patients in our centre during the study period was 0.4% (n=72). 90.9% of the case referred for UGIB were COVID-19 Category 4 patients who requires oxygen support(69%). 65% of them were started on anticoagulant and 70.8% were started on steroid therapy. The common presentation for UGIB in these patients were unexplained reduction in haemoglobin level(51.4%) and the most common endoscopic finding among 53% of the patient who were scoped was peptic ulcer(40%) .However, only 15% out of the 72 referred cases needed significant endoscopic intervention, i.e clipping, injection or cauterization. Mean systolic pressure of 148(p=0.006) and mean platelet level of less than 180(p=0.011) were found to be statistically significant in impacting the need for significant endoscopic intervention. The incidence of unplanned rescope and mortality were found to be not statistically impacted by endoscopic intervention done. Conclusion: Peptic ulcer disease is the most common finding in UGIB cases among COVID-19 patient. However endoscopic intervention was only needed in 15% of cases, therefore conservative management would be an acceptable option in management UGIB in COVID-19 patients. Disclaimer: Abstract text might vary slightly from what is displayed in the e-poster.  
Databáze: OpenAIRE